Table of Contents Author Guidelines Submit a Manuscript
Journal of Oncology
Volume 2018, Article ID 7863520, 8 pages
https://doi.org/10.1155/2018/7863520
Research Article

Experience and Expectations of Ovarian Cancer Patients in Australia

Centre for Community-Driven Research, Ultimo, NSW, Australia

Correspondence should be addressed to Catherine M. Holliday; gro.rd-cc@yadillohmc and Anne T. Holliday; gro.rd-cc@yadilloha

Received 27 November 2017; Accepted 31 January 2018; Published 7 March 2018

Academic Editor: John R. Van Nagell

Copyright © 2018 Catherine M. Holliday et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Some of the most significant advances in ovarian cancer treatment have been those that result in improvements in progression-free survival (PFS); however there is little research to understand the value that patients place on accessing therapies that result in PFS as a clinical outcome related to survivorship. This study therefore aimed to understand the experience and expectations of women with ovarian cancer in Australia in relation to quality of life (QoL) and treatment options. An online survey collected demographic information and 13 investigator-derived structured interview questions were developed to understand the experience of women with ovarian cancer, their understanding of terminology associated with their condition, and expectations of future treatment. This study demonstrated that ovarian cancer patients equate PFS with being in remission and that patients expect QoL during that time to be good to excellent. Women in this study described excellent QoL as feeling positive and happy and not worrying about cancer, feeling fit and healthy without side effects, and being able to live life as they did before their diagnosis, including the absence of fear of progression or recurrence. It is therefore suggested that there is a positive relationship between PFS and QoL. While it is difficult to quantify QoL and further research is needed, the results of this study suggest that the minimum time that women with ovarian cancer expect in relation to treatments that result in PFS is approximately six months. In the absence of this information, decision-makers are left to make assumptions about the value women place on access to therapeutics that increase PFS, which for this type of cancer is an important aspect of survivorship.